Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: A case report with histopathological analysis

European Journal of Endocrinology

Volumn 168, Issue 6, 2013, Pages

  Scheffel, Rafael Selbach ^a   Dora, José Miguel ^a   Siqueira, Débora R ^a   Burttet, Lucas Medeiros ^a   Cerski, Marcelle R ^b   Maia, Ana Luiza ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; DOBUTAMINE; GLUCOCORTICOID; HYDROCORTISONE; LEVOTHYROXINE; NORADRENALIN; OMEPRAZOLE; PLACEBO; PROPRANOLOL; TROPONIN T; VANDETANIB;

ACUTE HEART FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTERY CATHETERIZATION; ARTICLE; ARTIFICIAL VENTILATION; AUTOPSY; BLOOD PRESSURE; CALCITONIN BLOOD LEVEL; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CASE REPORT; CENTRAL VENOUS PRESSURE; CERVICAL LYMPH NODE; CODON; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONTRAST ENHANCEMENT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EMERGENCY WARD; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HEART ARREST; HEART ATRIUM ENLARGEMENT; HEART EJECTION FRACTION; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXEMIA; LABORATORY TEST; LIVER METASTASIS; LUNG ARTERY PRESSURE; LUNG INFILTRATE; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDICAL HISTORY; METABOLIC ACIDOSIS; ONCOGENE RET; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION PRESSURE; RECURRENT DISEASE; REENTRY TACHYCARDIA; RESUSCITATION; STEROID THERAPY; SUPRAVENTRICULAR TACHYCARDIA; T WAVE INVERSION; THORAX PAIN; THORAX RADIOGRAPHY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TOXIC CARDIOMYOPATHY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; VASCULAR RESISTANCE;

ADULT; CARDIOMYOPATHIES; CLINICAL TRIALS, PHASE III AS TOPIC; FATAL OUTCOME; FEMALE; HEART FAILURE; HUMANS; MALE; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84877771688     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0015     Document Type: Article

References (18)

1. Ceolin L, Siqueira DR, Romitti M, Ferreira CV & Maia AL. Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms. International Journal of Molecular Sciences 2012 13 221-239. (doi:10.3390/ijms13010221)
2. Pacini F, Castagna MG, Cipri C & Schlumberger M. Medullary thyroid carcinoma. Clinical Oncology 2010 22 475-485. (doi:10.1016/j.clon.2010.05.002)
3. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012 30 134-141. (doi:10.1200/JCO.2011.35.5040)
4. US. Food and Drug Administration. Highlights of Prescribing Information, http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022405s000lbl.pdf.
5. Force T, Krause DS & Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews. Cancer 2007 7 332-344. (doi:10.1038/nrc2106) (Pubitemid 46652481)
6. Madonna R & De Caterina R. VEGF receptor switching in heart development and disease. Cardiovascular Research 2009 84 4-6. (doi:10.1093/cvr/cvp270)
7. Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH & Force T. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clinical and Translational Science 2009 2 15-25. (doi:10.1111/j.1752-8062.2008.00090.x)
8. Hasinoff BB & Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicology and Applied Pharmacology 2010 249 132-139. (doi:10.1016/j.taap.2010.08.026)
9. Raschi E & De Ponti F. Cardiovascular toxicity of anticancertargeted therapy: emerging issues in the era of cardio-oncology. Internal and Emergency Medicine 2012 7 113-131. (doi:10.1007/s11739-011-0744-y)
10. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M & Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2008 26 5204-5212. (doi:10.1200/JCO.2007.15.6331)
11. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007 370 2011-2019. (doi:10.1016/S0140-6736(07)61865-0) (Pubitemid 350236338)
12. Aguirre SA, Heyen JR, Collette W, Bobrowski W & Blasi ER. Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor. Toxicologic Pathology 2010 38 416-428. (doi:10.1177/0192623310364027)
13. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR & White HD. Third universal definition of myocardial infarction. European Heart Journal 2012 33 2551-2567. (doi:10.1093/eurheartj/ehs184)
14. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J II, Champion JC, Durand JB & Lenihan DJ. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008 112 2500-2508. (doi:10.1002/cncr.23460)
15. Kwong RY & Korlakunta H. Diagnostic and prognostic value of cardiac magnetic resonance imaging in assessing myocardial viability. Topics in Magnetic Resonance Imaging 2008 19 15-24. (doi:10.1097/RMR.0B013e31817d550c)
16. Lawley C,Wainwright C, Segelov E, Lynch J, Beith J & McCrohon J. Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. Asia-Pacific Journal of Clinical Oncology 2012 8 95-100. (doi:10.1111/j.1743-7563.2011.01462.x)
17. Arques S. Contribution of natriuretic peptide testing and Doppler echocardiography at bedside to the diagnosis of acute heart failure. Apractical overview. Minerva Cardioangiologica 2012 60 385-394.
18. Lenihan DJ & Cardinale DM. Late cardiac effects of cancer treatment. Journal of Clinical Oncology 2012 30 3657-3664. (doi:10.1200/JCO.2012.45.2938)